Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
about
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapyInhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer.Acute sterile endophthalmitis following intravitreal bevacizumab: case series.Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.Intravitreal Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Several Years On.Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis)Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protHypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.Antiangiogenesis therapy: an update after the first decade.A Large Outbreak of Fulminant Bacterial Endophthalmitis after Intravitreal Injection of Counterfeit Bevacizumab.Is Spectral-Domain Optical Coherence Tomography Always Able to Detect the Anti-Vascular Endothelial Growth Factor Action on Neovascular Membrane?Outcomes of 23-Gauge Vitrectomy Combined with Phacoemulsification, Panretinal Photocoagulation, and Trabeculectomy without Use of Anti-VEGF Agents for Neovascular Glaucoma with Vitreous Hemorrhage.Clinical pharmacology of intravitreal anti-VEGF drugs.Abscisic acid: an antiangiogenic phytohormone that modulates the phenotypical plasticity of endothelial cells and macrophages.A novel peptide specifically binding to VEGF receptor suppresses angiogenesis and
P2860
Q28067341-BF8E920E-89C8-43A4-A71B-CE0C58516F2AQ33961137-4DAF75BA-68B8-442D-802E-EA4CEA6C75FFQ34182273-EEB6E3E5-4B1C-49A9-BDD0-872BC9796E41Q34987495-96760F6B-859B-431B-8E15-7B01BA24421DQ35002314-32CEF965-15AD-4CB9-A932-611352193747Q35027435-AC67C23C-60DD-459A-B63C-A61A24F94294Q35696092-E6CBF0D8-BABB-47CB-8E61-CCED5C951189Q36311337-B2FB68D6-5293-4B25-92A9-2C0CE3D25CAFQ38108833-3D75C88D-AAD9-4BDE-ACC2-5A32E84DF1DAQ38191586-EC1E1622-C42A-4CC2-8785-0E137A4C83CEQ40625734-8FF99FDA-62FD-47B1-9EA4-307204197134Q41898073-8F0CF8C3-4D5C-45D9-8741-A670E99A20DDQ42548364-25E3AF48-1FD8-4626-97A1-2CAD204DE71EQ48109878-31C13FD0-23B8-46B8-9B0C-754BA203DCD2Q48183508-31647B69-DCAB-42E6-88BA-FD30D16F21ABQ56890125-AD4C8E12-2F0D-48C2-BF7A-BCF5AD5C572C
P2860
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@ast
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@en
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@nl
type
label
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@ast
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@en
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@nl
prefLabel
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@ast
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@en
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@nl
P2860
P356
P1476
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
@en
P2093
Kenichi Kimoto
Toshiaki Kubota
P2860
P304
P356
10.1155/2012/852183
P577
2011-11-03T00:00:00Z